Type IIB von Willebrand's disease is a distinct form of this disorder, in which there are abnormal factor VIII/von Willebrand factor multimers in plasma (but normal multimers in platelets) and heightened interaction between the von Willebrand factor and platelets in the presence of ristocetin. We have found that infusion of desmopressin acetate (1-desamino-8-D-arginine vasopressin [DDAVP]), an agent used in the treatment of von Willebrand's disease, causes platelet aggregation and thrombocytopenia in patients with Type IIB disease. In vitro, platelets in normal plasma and those obtained from patients with Type IIB disease before DDAVP infusion aggregated upon the addition of platelet-poor plasma from Type IIB patients treated with DDAVP. Platelet aggregation was associated with adsorption of multimers of factor VIII/von Willebrand factor onto the platelets and was inhibited by EDTA. We conclude that in Type IIB von Willebrand's disease, DDAVP releases an abnormal factor with platelet-aggregating properties. DDAVP should not be used to treat patients with Type IIB disease, since the presence of platelet aggregates in the circulation may be harmful.
This article has been cited by other articles:
Federici, A. B., Mannucci, P. M., Castaman, G., Baronciani, L., Bucciarelli, P., Canciani, M. T., Pecci, A., Lenting, P. J., De Groot, P. G.
(2009). Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood
113: 526-534
[Abstract][Full Text]
Mannucci, P. M.
(2004). Treatment of von Willebrand's Disease. NEJM
351: 683-694
[Full Text]
Federici, A. B., Mazurier, C., Berntorp, E., Lee, C. A., Scharrer, I., Goudemand, J., Lethagen, S., Nitu, I., Ludwig, G., Hilbert, L., Mannucci, P. M.
(2004). Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood
103: 2032-2038
[Abstract][Full Text]
Mannucci, P. M.
(2001). How I treat patients with von Willebrand disease. Blood
97: 1915-1919
[Abstract][Full Text]
Pareti, F. I., Lattuada, A., Bressi, C., Zanobini, M., Sala, A., Steffan, A., Ruggeri, Z. M.
(2000). Proteolysis of von Willebrand Factor and Shear Stress-Induced Platelet Aggregation in Patients With Aortic Valve Stenosis. Circulation
102: 1290-1295
[Abstract][Full Text]
Allen, G. C., Armfield, D. R., Bontempo, F. A., Kingsley, L. A., Goldstein, N. A., Post, J. C.
(1999). Adenotonsillectomy in Children With von Willebrand Disease. Arch Otolaryngol Head Neck Surg
125: 547-551
[Abstract][Full Text]
Mauz-Körholz, C, Budde, U, Kruck, H, Körholz, D, Göbel, U
(1998). Management of severe chronic thrombocytopenia in von Willebrand's disease type 2B. Arch. Dis. Child.
78: 257-260
[Abstract][Full Text]
Mannucci, P. M.
(1997). Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years. Blood
90: 2515-2521
[Full Text]
Fresh-Frozen Plasma, Cryoprecipitate, and Platelet, , Cooper, E. S., Bracey, A. W., Horvath, A. E., Shanberge, J. N., Simon, T. L., Yawn, D. H.
(1994). Practice Parameter for the Use of Fresh-Frozen Plasma, Cryoprecipitate, and Platelets. JAMA
271: 777-781
[Abstract]
KOBRINSKY, N. L., LETTS, R. M., PATEL, L. R., ISRAELS, E. D., MONSON, R. C., SCHWETZ, N., CHEANG, M. S.
(1987). 1-Desamino-8-D-arginine Vasopressin (Desmopressin) Decreases Operative Blood Loss in Patients Having Harrington Rod Spinal Fusion Surgery: A Randomized, Double-Blinded, Controlled Trial. ANN INTERN MED
107: 446-450
[Abstract]
RICHARDSON, D. W., ROBINSON, A. G.
(1985). Drugs Five Years Later: Desmopressin. ANN INTERN MED
103: 228-239
[Abstract]
de la FUENTE, B., KASPER, C. K., RICKLES, F. R., HOYER, L. W.
(1985). Response of Patients with Mild and Moderate Hemophilia A and von Willebrand's Disease to Treatment with Desmopressin. ANN INTERN MED
103: 6-14
[Abstract]
Previous
